Given Imaging Ltd. (Nasdaq: GIVN; TASE: GIVN) has disclosed a study published in the July issue of the "Journal of Pediatric Gastroenterology and Nutrition", which found that the company's PillCam capsule endoscopy of the small bowel may enable more targeted and effective therapies for children with Crohn's disease.
The study said that the opportunities for improved treatment regimens were a direct result of reclassifying inflammatory bowel disease from ulcerative or indeterminate colitis to definitive Crohn's disease and from uncovering a more significant burden of small bowel disease for those children already diagnosed with Crohn's disease.
The study found that 71% of patients with ulcerative or indeterminate colitis were reclassified as having Crohn's disease, which led to a change in treatment. 62% of patients with Crohn's disease were found to have more extensive small bowel disease than previously identified.
The study was conducted by Dr. Stanley Cohen of the Children's Center for Digestive Healthcare in Atlanta. He said, "PillCam SB is a valuable tool that allows gastroenterologists to make better medical decisions and tailor pharmacological management, resulting in improved patient outcomes for those who suffer from inflammatory bowel disease. Information obtained through PillCam SB capsule endoscopy can enable us to reclassify disease or understand the full extent to which the disease is affecting patients, thus facilitating more targeted and effective treatment regimens."
Given Imaging rose 0.8% on Nasdaq yesterday to $15.13.
Published by Globes [online], Israel business news - www.globes-online.com - on July 10, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008